UK Plans National Rollout of Libido-Suppressing Drugs for Sex Offenders by December 2028

Drugs that help control the libidos of people who have committed sexual offences could be rolled out for thousands of male prisoners in England and Wales from December 2028, according to Prof Belinda Winder, a leading forensic psychologist who has evaluated the use of sex drive-suppressing medication in prisons.

Winder said about one in four sex offenders – equating to 3,750 current prisoners – would be considered for the treatment. Government sources have told the Guardian that Andy Burnham's administration is keen to expand the voluntary use of sex drive-suppressing drugs amid a scramble to ease the prison overcrowding crisis. However, ministers are re-evaluating whether to press ahead with Shabana Mahmood's pledge to explore mandatory chemical castration of serious sex offenders, such as paedophiles and rapists.

About 15,000 prisoners in England and Wales are serving a sentence for a sexual offence, and more than 850 men a month are arrested on suspicion of online child sexual abuse offences.

The MMPSA Treatment Pathway

A pilot programme, the medication to manage problematic sexual arousal (搜索)搜索该疾病 treatment pathway (MMPSA), will be expanded from 10 to 20 prisons in November. The next phase will extend from south-west England into two additional NHS regions, the north-west and north-east.

The programme targets sex offenders who experience intrusive, persistent and intense sexual thoughts, persistent arousal, and unhealthy sexual urges and sexual behaviours. Prisoners on the trial can be offered drugs including selective serotonin reuptake inhibitors查看药品详情 (SSRIs), such as sertraline查看药品详情, which helps to limit invasive sexual thoughts, and anti-androgens查看药品详情, which reduce the production of testosterone查看药品详情 and limit libido. In some cases, it reduces testosterone to pre-pubescent levels.

Winder said officials could be ready to launch the drugs in prisons and probation services across England and Wales within 28 months if the pilot continued to progress. "They [the Ministry of Justice (搜索)搜索该词条] could be ready in December 2028 to roll the programme out if the interim findings look useful," she said.

Clinical Support and the Voluntary Model

Those on the scheme would have to receive clinical support if they were to commit to taking the drugs and not reoffend, Winder said. "I am optimistic that a properly resourced, voluntary national MMPSA pathway could ultimately be developed … A good national service needs appropriately trained clinicians, clear referral routes, appropriate psychological support alongside medication," she said.

Last year Mahmood, the then justice secretary, told MPs she was exploring a national rollout of voluntary chemical castration for sex offenders and whether it could be made mandatory. Two experts have told the Guardian that the plan will not work. Winder, a co-chief investigator of a Prozac查看药品详情 clinical trial with sex offenders, said she had significant concerns.

"A mandatory approach would require screening a very large prison population to identify the much smaller group for whom treatment might actually be appropriate," she said. "It would have substantial clinical and resource implications."

There were also concerns that if it was mandatory, there could be a breakdown of trust with offenders and it could be open to abuse, she said. "Trying to impose and monitor daily medication among people who do not necessarily want to take it could be extremely inefficient. It could also introduce a range of consequences that we simply do not yet understand, including effects on trust, disclosure, engagement and the therapeutic relationship."

She rejected characterising the drugs as a form of "chemical castration". "People say that because some people like the idea of castrating people who commit sexual offences," she said. "But these drugs are not permanent, unlike castration, and must be taken consistently to work."

How the Drugs Work

For some prisoners with problematic sexual arousal (搜索)搜索该疾病 (PSA), "images of sex flood their minds" all of their waking hours, according to Winder. "I remember talking to one guy a few weeks after he started taking the medication. He said: 'It's amazing. I followed a film plot. I wasn't just looking for when I could see bra straps, when I could see nipples, when someone's going to bend over so I could see their bum.'"

"Without the drugs, these images were going around his head all the time. He did not want them any more," she said.

Drugs used in the UK to treat PSA include antidepressants, which help control obsessive urges, and anti-androgens查看药品详情, which lower testosterone查看药品详情 levels. The treatments, typically taken as pills, are not suitable for some offenders such as those who are primarily motivated by anger, or who struggle to moderate their behaviour while using alcohol or drugs.

International Context and Ethical Considerations

A similar approach has been used in some European countries. In Denmark and France, the use of chemical suppression has only been administered on a voluntary basis. In Germany, the Dunkelfeld project provides free and confidential therapies including medical interventions to men with paedophilic or hebephilic obsessions.

But many other countries have taken a harder line. Poland introduced mandatory chemical suppression for some sex offenders. South Korea became the first country in Asia to legalise chemical castration, passing a law in 2010. In Australia, several states grant courts and parole boards the power to order anti-libidinal treatment for high-risk sex offenders which can then become a condition of release. Kazakhstan and a number of US states including California and Florida already have mandatory prescribing of anti-libidinal drugs to some sex offenders.

Officials in the UK have explored whether taking part in programmes such as these could be made a condition of a parole licence, similar to a scheme in California. However, ethical dilemmas remain over whether it would be right to give someone parole based on whether they take a drug that can be life-changing.

Each offender would have to be assessed by the Parole Board on their merits, according to Winder. "It is never going to be so simple that a decision will be taken on whether to give someone parole based on whether they are taking their meds," she said.

Safety Concerns and Cautions

The side effects of anti-androgens查看药品详情 in particular can be severe. Some men experience fatigue, hot flushes, muscle loss, mood changes, weight gain and a loss of bone density. Prison campaigners have urged caution before going ahead with a national programme. Critics have previously pointed out that long-term testosterone查看药品详情 suppression can cause osteoporosis (搜索)搜索该疾病 and cardiovascular disease (搜索)搜索该疾病. There is limited data because randomised controlled trials remain scarce.

Experts acknowledge that problems remain. The medication is not a cure and does not change underlying behaviours. Some programmes have high drop-out rates.

Andrew Neilson, the director of campaigns at the Howard League for Penal Reform, said: "The history of prison-based treatment programmes in this area has proven troubled, which is both a reason for exploring alternatives but also a reason to exercise caution before expanding new approaches more widely. It's also important that nobody is forced into these chemical interventions and that participation is truly voluntary."

Mark Fairhurst, the national chair of the prison officers' union the POA, said: "Anything that potentially protects the public is welcome but I would be cautious about the rollout until we are in receipt of evidence that proves success."

There are comparatively low reoffending rates among sexual offenders compared with other cohorts. According to government data, 11.7% of sex offenders reoffended in 2023, compared with 53.9% of those with an index offence for theft.

A Ministry of Justice (搜索)搜索该词条 spokesperson said: "This government is determined to tackle the root causes of sex offending, which is why we're working at pace to extend the existing pilot to a further two regions."